Appili Therapeutics Secures $40 Million NIAID Contract for Antifungal Vaccine Development
核心洞察
Appili Therapeutics (搜索) received a $40 million NIAID (搜索) contract over five years to develop VXV-01 (搜索), a first-in-class dual-antigen vaccine targeting multidrug-resistant Candida species (搜索).
The company has $90 million in pending government funding proposals across multiple infectious disease programs, with awards potentially announced in Q1 2026.
LIKMEZ, the first FDA-approved liquid oral metronidazole formulation, showed steady sales growth following its May 2025 re-launch in the U.S. market.
Appili Therapeutics (搜索) has secured a major funding milestone with a $40 million contract from the National Institute of Allergy and Infectious Diseases (NIAID (搜索)) to advance VXV-01 (搜索), a novel vaccine targeting multidrug-resistant Candida infections (搜索). The five-year contract supports development through IND-enabling activities, IND submission, and Phase 1 clinical studies for this first-in-class, dual-antigen vaccine.
The Halifax-based infectious disease biopharmaceutical company announced these developments alongside its second quarter fiscal 2026 financial results, reporting a net loss of $1.0 million ($0.01 per share) for the three months ending September 30, 2025.
Strategic Government Funding Pipeline
"Strategic government partnerships are foundational to Appili's impact in infectious disease and biodefense," said Dr. Don Cilla, President and CEO of Appili. "The recent award of up to US$40 million for VXV-01 (搜索), developed in collaboration with Vitalex Biosciences (搜索), highlights the confidence the NIAID (搜索) placed in our execution, and empowers us to accelerate the development of much-needed solutions for urgent public health threats."
The company has submitted multiple funding proposals to U.S. government agencies representing approximately $90 million in potential awards. These proposals would support critical development activities including manufacturing optimization, preclinical studies, regulatory activities, IND submissions, and Phase 1 clinical trials. Appili anticipates awards from multiple proposals may be announced in the first quarter of calendar 2026.
To date, Appili and its partners have secured over $66 million in government contracts and grants, demonstrating the strength of its non-dilutive funding model that leverages public sector support without diluting shareholder value.
VXV-01 Addresses Critical Unmet Need
VXV-01 (搜索) is designed to address the urgent global need for improved fungal infection prophylaxis, especially in high-risk, immunocompromised groups, where current antifungal treatments are limited by resistance and toxicity. Under the executed agreement with Vitalex, Appili holds an exclusive option to acquire worldwide rights to the VXV-01 program, which would enable control over development, commercialization, and partnering activities.
Commercial Progress with LIKMEZ
Saptalis Pharmaceuticals (搜索), Appili's manufacturing and commercialization partner, successfully re-launched LIKMEZ (metronidazole oral suspension, 500 mg/5 mL) in the U.S. market as the first and only FDA-approved liquid oral formulation of metronidazole. Since the re-launch in May 2025, LIKMEZ has seen steady sales increases, reflecting strong demand among clinicians and patients seeking improved anti-infective therapy options.
Under the partnership terms, Appili is eligible to receive both milestone payments and ongoing royalties from LIKMEZ sales in the U.S., creating a growing source of commercial revenue.
Biodefense Vaccine Advances
ATI-1701, a live-attenuated vaccine candidate for tularemia (搜索), achieved key operational milestones during the quarter with successful GMP manufacture of drug substance and drug product at its contract manufacturing organization. The GMP drug product may be used in a Phase 1 clinical trial.
In September 2025, Dr. Carl Gelhaus presented new ATI-1701 data at the NATO Chemical, Biological, Radiological and Nuclear Conference, showcasing its promise as a first-in-class tularemia (搜索) vaccine for biodefense. A new peer-reviewed publication co-authored by Dr. Gelhaus demonstrated ATI-1701's durable protection in primate models, further advancing its momentum as a leading biodefense candidate.
Appili believes ATI-1701 will be eligible for a Priority Review Voucher when approved by the FDA, subject to renewal of pending U.S. legislation, representing the company's second potentially PRV-eligible asset.
Regulatory Progress for Leishmaniasis Treatment
ATI-1801, a novel topical formulation of paromomycin (15% w/w) for treating cutaneous leishmaniasis (搜索), is progressing toward NDA submission following positive FDA feedback on its scientific bridging strategy. The company is pursuing non-dilutive funding from global health organizations and strategic partners to accelerate the FDA-aligned development pathway.
Cutaneous leishmaniasis (搜索) is a serious and disfiguring skin disease affecting hundreds of thousands of individuals worldwide each year. Appili believes ATI-1801 may be eligible for a Priority Review Voucher when approved by the FDA, with PRVs recently monetized for amounts exceeding $150 million.
Financial Position
As of September 30, 2025, the company's cash balance was $0.3 million, down from $1.2 million as of March 31, 2025. The company had 121,266,120 issued and outstanding common shares, 11,910,281 stock options, and 34,930,000 warrants outstanding.